Literature DB >> 28898982

Prevalence of Anal Human Papillomavirus (HPV) and Performance of Cepheid Xpert and Hybrid Capture 2 (hc2) HPV Assays in South African HIV-Infected Women.

Zizipho Z A Mbulawa1,2, Timothy Wilkin3, Bridgette J Goeieman4, Eefje Jong5, Pamela Michelow6,7, Avril Swarts8, Jennifer S Smith9, Patricia Kegorilwe4, Cynthia S Firnhaber4,8, Anna-Lise Williamson1,10.   

Abstract

OBJECTIVES: This study investigated anal high-risk HPV (HR-HPV) prevalence in HIV-infected women using the Cepheid Xpert HPV assay and compares its performance with that of Hybrid Capture-2 (hc2).
METHODS: A total of 199 HIV-infected women were recruited from Helen Joseph Hospital, Johannesburg. Stored ThinPrep anal swabs that had previously been tested using hc2 were tested for HPV using Xpert.
RESULTS: The HR-HPV prevalence by Xpert was 40.8% and similar to hc2 (41.8%) with overall agreement of 86.7%; Cohen's kappa 0.73 (95% CI 0.63-0.82). High grade squamous intraepithelial lesions (HSIL) was associated with increasing number of multiple HPV infection (P < .001). Xpert and hc2 were similarly sensitive (77.4% and 77.4%, respectively) and specific (66.1% and 64.8% respectively) for HSIL detection. HPV16 (OR: 14.0, 95% CI: 3.9-48.0, P < .0001), HPV39/68/56/66 (OR: 4.1, 95% CI: 1.4-12, P = .01) and HPV51/59 (OR: 2.8, 95% CI: 1.1-7.6, P = .04) were independently associated with anal HSIL.
CONCLUSIONS: Xpert HPV typing is a promising anal screening test in HIV-infected women that performs similarly to hc2. © American Society for Clinical Pathology, 2017. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  Anal cancer; HPV; Women; Xpert; hc2

Mesh：

Year:  2017        PMID： 28898982      PMCID： PMC5848307          DOI： 10.1093/ajcp/aqx050

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


  21 in total

1.  Prevalence of Anal HPV and Anal Dysplasia in HIV-Infected Women From Johannesburg, South Africa.

Authors:  Bridgette J Goeieman; Cynthia S Firnhaber; Eefje Jong; Pam Michelow; Patricia Kegorilwe; Avril Swarts; Anna-Lise Williamson; Bruce Allan; Jennifer S Smith; Timothy J Wilkin
Journal:  J Acquir Immune Defic Syndr       Date:  2017-07-01       Impact factor: 3.731

2.  Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).

Authors:  Kate Cuschieri; Daan Geraets; Jack Cuzick; Louise Cadman; Catherine Moore; Davy Vanden Broeck; Elisaveta Padalko; Wim Quint; Marc Arbyn
Journal:  J Clin Microbiol       Date:  2016-07-06       Impact factor: 5.948

Review 3.  HPV in genital cancers (at the exception of cervical cancer) and anal cancers.

Authors:  Silvia de Sanjosé; Laia Bruni; Laia Alemany
Journal:  Presse Med       Date:  2014-10-30       Impact factor: 1.228

4.  High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men.

Authors:  J M Palefsky; E A Holly; M L Ralston; N Jay; J M Berry; T M Darragh
Journal:  AIDS       Date:  1998-03-26       Impact factor: 4.177

Review 5.  Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions.

Authors:  Brooke E Hoots; Joel M Palefsky; Jeanne M Pimenta; Jennifer S Smith
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

6.  Anal cancers among HIV-infected persons: HAART is not slowing rising incidence.

Authors:  Nancy F Crum-Cianflone; Katherine Huppler Hullsiek; Vincent C Marconi; Anuradha Ganesan; Amy Weintrob; Robert V Barthel; Brian K Agan
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

7.  Human papillomavirus genotype specificity of hybrid capture 2.

Authors:  Philip E Castle; Diane Solomon; Cosette M Wheeler; Patti E Gravitt; Sholom Wacholder; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

Review 8.  The epidemiology of anal human papillomavirus and related neoplasia.

Authors:  Joel M Palefsky; Mary Rubin
Journal:  Obstet Gynecol Clin North Am       Date:  2009-03       Impact factor: 2.844

9.  Clinical Performance Validation of 4 Point-of-Care Cervical Cancer Screening Tests in HIV-Infected Women in Zambia.

Authors:  Carla J Chibwesha; Brigitte Frett; Katundu Katundu; Allen C Bateman; Aaron Shibemba; Sharon Kapambwe; Mulindi H Mwanahamuntu; Susan Banda; Chalwa Hamusimbi; Pascal Polepole; Groesbeck P Parham
Journal:  J Low Genit Tract Dis       Date:  2016-07       Impact factor: 1.925

10.  Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica.

Authors:  Felipe A Castro; Wim Quint; Paula Gonzalez; Hormuzd A Katki; Rolando Herrero; Leen-Jan van Doorn; Mark Schiffman; Linda Struijk; Ana Cecilia Rodriguez; Corey DelVecchio; Douglas R Lowy; Carolina Porras; Silvia Jimenez; John Schiller; Diane Solomon; Sholom Wacholder; Allan Hildesheim; Aimée R Kreimer
Journal:  J Infect Dis       Date:  2012-07-30       Impact factor: 5.226
View more
  4 in total

1.  Cervical human papillomavirus DNA detection in women living with HIV and HIV-uninfected women living in Limbe, Cameroon.

Authors:  Adebola Adedimeji; Rogers Ajeh; Anastase Dzudie; Ernestine Kendowo; Norbert Fuhngwa; Denis Nsame; Andre Gaetan Simo-Wambo; Enow Orock; Tiffany M Hebert; Amanda J Pierz; Daniel Murokora; Kathryn Anastos; Philip E Castle
Journal:  J Clin Virol       Date:  2020-05-19       Impact factor: 3.168

2.  Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV.

Authors:  Grant B Ellsworth; Elizabeth A Stier; Elizabeth Y Chiao; Shelly Y Lensing; Teresa Darragh; Naomi Jay; J Michael Berry-Lawhorn; Mark Einstein; Luis F Barroso; Ross D Cranston; Rebecca Levine; Humberto M Guiot; Audrey L French; Stephen E Goldstone; Wolfgang Preiser; Mathilda Claassen; Joel M Palefsky; Timothy J Wilkin
Journal:  J Acquir Immune Defic Syndr       Date:  2021-07-01       Impact factor: 3.771

3.  Prevalence and genotype specific concordance of oro-genital and anal human papillomavirus infections among sexually active Nigerian women.

Authors:  Imran O Morhason-Bello; Kathy Baisley; Miquel Angel Pavon; Isaac F Adewole; Rasheed Bakare; Silvia de Sanjosé; Suzanna C Francis; Deborah Watson-Jones
Journal:  Infect Agent Cancer       Date:  2021-09-08       Impact factor: 2.965

4.  Comparison of the Cepheid Xpert HPV test and the HC2 High-Risk HPV DNA Test for detection of high-risk HPV infection in cervical smear samples in SurePath preservative fluid.

Authors:  Ali A Rabaan; Shatha A Alfaraj; Mohammed A Alkhalifah
Journal:  J Med Microbiol       Date:  2018-05       Impact factor: 2.472
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.